Kura Oncology (KURA) Stock Price, Quote & News

Company Profile

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabe...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 500 8800

Website: kuraoncology.com

Address:

4930 Directors Place, Suite 500, San Diego, United States

WallStreetBuyDip Apr. 3 at 8:37 PM

$KURA Massive volume spike on Apr 2, 2026, with 4.3M shares traded, significantly higher than the average volume of 1.6M. Recent price action shows a jump from $7.74 to $8.61. Keep an eye on this one and wait for a lower H% before considering an entry.

0 · Reply

RunnerSignals Apr. 3 at 1:27 PM

$VSAT $AAOI $AXTI $KURA $DBVT RSI flip = early money signal not extended yet, setups still developing https://stocksrunner.com/news/2026-04-03-momentum-rsi-breakout

0 · Reply

ITrustno1 Apr. 2 at 9:29 PM

$KURA 4.3mil total 🧘

0 · Reply

ITrustno1 Apr. 2 at 3:33 PM

$KURA double the avg daily volume in just first 2hrs… 😎

0 · Reply

PennyPoacher Apr. 2 at 3:27 PM

$KURA big volume today

0 · Reply

MR2601 Apr. 2 at 3:00 PM

$KURA is substantially undervalued ; a very good buy and hold stock

0 · Reply

ITrustno1 Mar. 30 at 9:33 PM

$KURA the hope would be some short covering down here at this level to reduce the overall percentage by EOD tomorrow.

0 · Reply

PennyPoacher Mar. 27 at 8:07 PM

$KURA I’ve got a couple small extended hours sitting at 7.48. Highly doubt they’ll fill

1 · Reply

TV8 Mar. 27 at 7:41 PM

$KURA To be fair most stocks in the red today, everyone heading for cover. We need good guidance soon, some pre lim results and good earnings.

1 · Reply

Olena Mar. 27 at 6:47 PM

$KURA nothing is about stock performance any more. Politics rules everything today

1 · Reply

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 2, 2026, 8:15 AM EDT - 3 days ago

Kura Oncology: Commercialization In AML Presents Asymmetric Upside

Mar 12, 2026, 4:02 PM EDT - 23 days ago

Kura Oncology, Inc. (KURA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mar 5, 2026, 12:45 PM EST - 4 weeks ago

Kura Oncology, Inc. (KURA) Q4 2025 Earnings Call Transcript

Mar 5, 2026, 6:31 AM EST - 4 weeks ago

Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 26, 2026, 7:30 AM EST - 5 weeks ago

Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results

Feb 25, 2026, 7:30 AM EST - 5 weeks ago

Kura Oncology to Participate in Three Upcoming Investor Conferences

Jan 22, 2026, 7:34 AM EST - 2 months ago

Kura Oncology: Safety Profile Of Komzifti Supports My Upgrade To Strong Buy

Jan 11, 2026, 5:00 PM EST - 2 months ago

Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones

$Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML Transcript$

Dec 8, 2025, 5:17 PM EST - 4 months ago

Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML Transcript

$Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML$

Dec 8, 2025, 10:30 AM EST - 4 months ago

Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML

Dec 4, 2025, 8:08 AM EST - 4 months ago

Kura Oncology: A Cautious Buy

$Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia$

Dec 3, 2025, 8:32 AM EST - 4 months ago

Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia

Dec 2, 2025, 6:36 PM EST - 4 months ago

Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data

Dec 2, 2025, 8:02 AM EST - 4 months ago

First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin

Nov 25, 2025, 5:16 PM EST - 4 months ago

KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)

$Kura Oncology, Inc. (KURA) Discusses FDA Approval of KOMZIFTI for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia Transcript$

Nov 19, 2025, 5:23 PM EST - 4 months ago

Kura Oncology, Inc. (KURA) Discusses FDA Approval of KOMZIFTI for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia Transcript

$Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia$

Nov 13, 2025, 10:51 AM EST - 5 months ago

Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

Nov 13, 2025, 10:32 AM EST - 5 months ago

US FDA approves Kura Oncology's blood cancer therapy

Nov 12, 2025, 4:05 PM EST - 5 months ago

Kura Oncology to Participate in Upcoming Investor Conference

Nov 4, 2025, 3:46 PM EST - 5 months ago

Kura Oncology, Inc. (KURA) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 6:31 AM EST - 5 months ago

Kura Oncology Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 4:02 PM EST - 5 months ago

Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin

$Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting$

Nov 3, 2025, 9:14 AM EST - 5 months ago

Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting

Nov 2, 2025, 9:00 AM EST - 5 months ago

Kura Oncology's Ziftomenib Poised For Differentiation

Oct 28, 2025, 4:01 PM EDT - 5 months ago

Kura Oncology to Report Third Quarter 2025 Financial Results

Oct 24, 2025, 7:02 AM EDT - 5 months ago

Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin

Oct 18, 2025, 6:56 PM EDT - 6 months ago

Kura Oncology, Inc. (KURA) Discusses Clinical Updates on Farnesyl Transferase Inhibitor Programs and Combination Therapies in Oncology Transcript

Oct 18, 2025, 3:23 AM EDT - 6 months ago

Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress

Oct 1, 2025, 5:02 PM EDT - 6 months ago

Kura Oncology, Inc. (KURA) Presents at UBS Virtual Oncology Day Transcript

Oct 1, 2025, 7:01 AM EDT - 6 months ago

Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Sep 29, 2025, 4:01 PM EDT - 6 months ago

Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)

$Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology$

Sep 25, 2025, 5:18 PM EDT - 6 months ago

Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology

Sep 19, 2025, 11:03 AM EDT - 7 months ago

Kura Oncology Transitioning To Commercial Stage: Why I Choose To Buy

Sep 16, 2025, 10:53 PM EDT - 7 months ago

Kura Oncology, Inc. - Special Call

Sep 16, 2025, 4:01 PM EDT - 7 months ago

Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types

Sep 10, 2025, 4:44 PM EDT - 7 months ago

Kura Oncology, Inc. (KURA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 3, 2025, 8:02 AM EDT - 7 months ago

Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program

Aug 9, 2025, 10:46 PM EDT - 8 months ago

Kura Oncology, Inc. (KURA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 8 months ago

Kura Oncology Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 7:30 AM EDT - 8 months ago

Kura Oncology to Report Second Quarter 2025 Financial Results

Jul 2, 2025, 12:09 AM EDT - 9 months ago

Kura Oncology: Ziftomenib Shift Towards Newly Diagnosed Mutant AML Patients Bodes Well

Jun 12, 2025, 7:30 AM EDT - 10 months ago

Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress

Jun 2, 2025, 6:00 PM EDT - 10 months ago

Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting

$Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML$

Jun 1, 2025, 7:00 PM EDT - 10 months ago

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

May 22, 2025, 5:30 PM EDT - 11 months ago

Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting

May 14, 2025, 10:00 AM EDT - 11 months ago

Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress

May 6, 2025, 7:30 AM EDT - 11 months ago

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

May 1, 2025, 8:48 PM EDT - 1 year ago

Kura Oncology, Inc. (KURA) Q1 2025 Earnings Call Transcript

May 1, 2025, 4:05 PM EDT - 1 year ago

Kura Oncology Reports First Quarter 2025 Financial Results

WallStreetBuyDip Apr. 3 at 8:37 PM

0 · Reply

RunnerSignals Apr. 3 at 1:27 PM

$VSAT $AAOI $AXTI $KURA $DBVT RSI flip = early money signal not extended yet, setups still developing https://stocksrunner.com/news/2026-04-03-momentum-rsi-breakout

0 · Reply

ITrustno1 Apr. 2 at 9:29 PM

$KURA 4.3mil total 🧘

0 · Reply

ITrustno1 Apr. 2 at 3:33 PM

$KURA double the avg daily volume in just first 2hrs… 😎

0 · Reply

PennyPoacher Apr. 2 at 3:27 PM

$KURA big volume today

0 · Reply

MR2601 Apr. 2 at 3:00 PM

$KURA is substantially undervalued ; a very good buy and hold stock

0 · Reply

ITrustno1 Mar. 30 at 9:33 PM

$KURA the hope would be some short covering down here at this level to reduce the overall percentage by EOD tomorrow.

0 · Reply

PennyPoacher Mar. 27 at 8:07 PM

$KURA I’ve got a couple small extended hours sitting at 7.48. Highly doubt they’ll fill

1 · Reply

TV8 Mar. 27 at 7:41 PM

$KURA To be fair most stocks in the red today, everyone heading for cover. We need good guidance soon, some pre lim results and good earnings.

1 · Reply

Olena Mar. 27 at 6:47 PM

$KURA nothing is about stock performance any more. Politics rules everything today

1 · Reply

PennyPoacher Mar. 27 at 6:29 PM

$KURA just sold some 7.50 puts. Let’s see how this shakes out

0 · Reply

AdiDasRom Mar. 27 at 6:22 PM

$KURA It seems like it's getting close to the cash price. Absurd. Someone will take full advantage of this drop.

1 · Reply

PennyPoacher Mar. 27 at 4:25 PM

$KURA what book value on this?

1 · Reply

PennyPoacher Mar. 27 at 4:24 PM

$KURA ruthless, time to start loading the boat. I wouldn’t be surprised to see us around 7.50 come April OPEX (4/17)

0 · Reply

AdiDasRom Mar. 27 at 4:15 PM

$KURA

0 · Reply

Olena Mar. 27 at 3:44 PM

$KURA so tired of this bottom fishing. Time to go to double digits

0 · Reply

blueb22 Mar. 26 at 8:16 PM

$KURA - I believe Troy freed up good chunk of Money (atleast $5M) from Avidity merger close, so I think he must be Buying or about to buy good amount of Kura shares in open market. We will know soon. And when he release on SEC form, it will help stock go up 10-15% quickly.

0 · Reply

CH_Expat Mar. 26 at 7:51 PM

$KURA Trades like dogshit for a reason. Undervalued though, therefore I remain invested with a small position. Launch underwhelming, KK deal still sucks.

1 · Reply

gazza75799 Mar. 26 at 2:25 AM

$KURA the top resistance on this small mountain (from the large shadow on the left) is insane. Leave it alone, waist of capital

1 · Reply

AdiDasRom Mar. 25 at 2:12 PM

$KURA is much more delicious.

0 · Reply

CyberCuba Mar. 25 at 1:43 PM

$KURA TERNS is a no commercially approved leukemia drug company whereas KURA has an approved leukemia drug. Stay long!

0 · Reply

Oscarca Mar. 25 at 9:19 AM

$KURA Great company and still the stock price ain’t reflecting that ..

0 · Reply

Market Cap	760.52M
Revenue (ttm)	67.48M
Net Income (ttm)	-278.67M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-412.97%
Debt to Equity Ratio	0.06

Volume	4,391,900
Avg Vol	1,516,372
Day's Range	N/A - N/A
Shares Out	88.33M
Stochastic %K	77%
Beta	0.25
Analysts	Strong Sell
Price Target	$31.91